Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:MDT
CUSIP58505510
Phone353-1438-1700
Debt
Debt-to-Equity Ratio0.47
Current Ratio2.28
Quick Ratio1.92
Price-To-Earnings
Trailing P/E Ratio18.45
Forward P/E Ratio17.23
P/E Growth2.42
Sales & Book Value
Annual Sales$29.95 billion
Price / Sales3.97
Cash Flow$6.7294 per share
Price / Cash13.08
Book Value$37.50 per share
Price / Book2.35
Profitability
EPS (Most Recent Fiscal Year)$4.77
Net Income$3.10 billion
Net Margins10.36%
Return on Equity12.84%
Return on Assets6.84%
Miscellaneous
Employees86,000
Outstanding Shares1,351,710,000
Market Cap$119,518.12
Medtronic (NYSE:MDT) Frequently Asked Questions
What is Medtronic's stock symbol?
Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."
How often does Medtronic pay dividends? What is the dividend yield for Medtronic?
Medtronic announced a quarterly dividend on Friday, June 22nd. Shareholders of record on Friday, July 6th will be paid a dividend of $0.50 per share on Wednesday, July 25th. This represents a $2.00 dividend on an annualized basis and a yield of 2.27%. The ex-dividend date of this dividend is Thursday, July 5th. This is a boost from Medtronic's previous quarterly dividend of $0.46. View Medtronic's Dividend History.
How will Medtronic's stock buyback program work?
Medtronic declared that its Board of Directors has approved a stock repurchase plan on Thursday, October 5th 2017, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 49% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its shares are undervalued.
How were Medtronic's earnings last quarter?
Medtronic PLC (NYSE:MDT) announced its quarterly earnings results on Thursday, May, 24th. The medical technology company reported $1.42 EPS for the quarter, beating analysts' consensus estimates of $1.39 by $0.03. The medical technology company earned $8.14 billion during the quarter, compared to the consensus estimate of $8 billion. Medtronic had a return on equity of 12.84% and a net margin of 10.36%. The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period last year, the business earned $1.33 earnings per share. View Medtronic's Earnings History.
When is Medtronic's next earnings date?
What guidance has Medtronic issued on next quarter's earnings?
Medtronic updated its FY19 earnings guidance on Thursday, May, 24th. The company provided earnings per share guidance of $5.10-5.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.14.
What price target have analysts set for MDT?
23 brokerages have issued 12 month price targets for Medtronic's stock. Their forecasts range from $80.00 to $103.00. On average, they expect Medtronic's share price to reach $92.5750 in the next twelve months. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Ratings for Medtronic.
What is the consensus analysts' recommendation for Medtronic?
23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 7 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Medtronic stock?
Here are some recent quotes from research analysts about Medtronic stock:
- 1. According to Zacks Investment Research, "Medtronic exited the fiscal second quarter on a mixed note. While the company demonstrated improved segmental performances at CER, escalating costs and expenses continue to weigh on the bottom line. Unfavorable currency translation also acted as a dampener. On the bright side, all major business groups contributed to solid top-line growth at CER, which highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. We are also encouraged by the solid growth trend in the United States as well as healthy global acceptance of its advanced therapies. The recent receipt of FDA approval and commercial launch of Azure pacemakers with BlueSync technology buoy optimism. Apart from product innovation, the company is focusing on geographical diversification of its businesses. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside." (11/23/2017)
- 2. Needham & Company LLC analysts commented, "On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model." (11/9/2017)
Who are some of Medtronic's key competitors?
Some companies that are related to Medtronic include SONOVA Hldg AG/ADR (SONVY), Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), AxoGen, Inc Common Stock (AXGN), NxStage Medical (NXTM), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), Electrocore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI) and Vision Sciences (CGNT).
Who are Medtronic's key executives?
Medtronic's management team includes the folowing people:
- Mr. Omar S. Ishrak, Chairman & CEO (Age 62)
- Ms. Karen L. Parkhill, Exec. VP & CFO (Age 53)
- Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 56)
- Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 57)
- Dr. David Neustaedter, VP, Venture Capital
Has Medtronic been receiving favorable news coverage?
News coverage about MDT stock has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medtronic earned a news impact score of 0.07 on Accern's scale. They also gave news stories about the medical technology company an impact score of 45.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Medtronic's major shareholders?
Medtronic's stock is owned by a number of of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.27%), Bank of Montreal Can (0.23%), Fred Alger Management Inc. (0.10%), Hexavest Inc. (0.09%), Gateway Investment Advisers LLC (0.08%) and Factory Mutual Insurance Co. (0.07%). Company insiders that own Medtronic stock include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz and Robert C Pozen. View Institutional Ownership Trends for Medtronic.
Which institutional investors are selling Medtronic stock?
MDT stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Bank of Montreal Can, Retirement Systems of Alabama, Fred Alger Management Inc., Hartford Investment Management Co., Nippon Life Global Investors Americas Inc., Meag Munich Ergo Kapitalanlagegesellschaft MBH and LS Investment Advisors LLC. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Hooman Hakami, James T Lenehan, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic.
Which institutional investors are buying Medtronic stock?
MDT stock was acquired by a variety of institutional investors in the last quarter, including Compass Capital Management Inc., Cornerstone Wealth Management LLC, Saratoga Research & Investment Management, Nelson Roberts Investment Advisors LLC, Cornerstone Investment Partners LLC, Calamos Advisors LLC, State of Alaska Department of Revenue and Hengehold Capital Management LLC. Company insiders that have bought Medtronic stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic.
How do I buy shares of Medtronic?
Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medtronic's stock price today?
One share of MDT stock can currently be purchased for approximately $88.02.
How big of a company is Medtronic?
Medtronic has a market capitalization of $119.52 billion and generates $29.95 billion in revenue each year. The medical technology company earns $3.10 billion in net income (profit) each year or $4.77 on an earnings per share basis. Medtronic employs 86,000 workers across the globe.
How can I contact Medtronic?
Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]
MarketBeat Community Rating for Medtronic (NYSE MDT)
MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
